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Abstract
Background: Recent advances in nanotechnology have led to the development of biocompatible nanoparticles for in vivo
molecular imaging and targeted therapy. Many nanoparticles have undesirable tissue distribution or unacceptably low
serum half-lives. Pharmacokinetic (PK) and biodistribution studies can help inform decisions determining particle size,
coatings, or other features early in nanoparticle development. Unfortunately, these studies are rarely done in a timely
fashion because many nanotechnology labs lack the resources and expertise to synthesize radioactive nanoparticles and
evaluate them in mice.
Methodology/Principal Findings: To address this problem, we developed an economical, radioactivity-free method for
assessing serum half-life and tissue distribution of nanoparticles in mice. Iron oxide nanoparticles coated with chitosan and
polyethylene glycol that utilize chlorotoxin as a targeting molecule have a serum half-life of 7–8 hours and the particles
remain stable for extended periods of time in physiologic fluids and in vivo. Nanoparticles preferentially distribute to spleen
and liver, presumably due to reticuloendothelial uptake. Other organs have very low levels of nanoparticles, which is ideal
for imaging most cancers in the future. No acute toxicity was attributed to the nanoparticles.
Conclusions/Significance: We report here a simple near-infrared fluorescence based methodology to assess PK properties of
nanoparticles in order to integrate pharmacokinetic data into early nanoparticle design and synthesis. The nanoparticles tested
demonstrate properties that are excellent for future clinical imaging strategies and potentially suitable for targeted therapy.
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Introduction
Nanomedicine, the application of nanotechnology in the
practice of medicine, offers many advantages over conventional
therapeutics. Properly developed, nanoparticles and other nano-
scale therapeutics offer improved intracellular penetration,
enhanced absorption into selected tissues, better pharmacokinetic
(PK) properties, increased clinical efficacy and reduced toxicity
[1]. Nanomedicine faces several challenges during preclinical
development. Recently, the Food and Drug Administration (FDA)
and the Alliance for NanoHealth (ANH) recognized seven
scientific challenges in bringing nanomedicine to patients [2].
Among the seven challenges, three emphasize the importance of
studying the pharmacokinetics of nanotechnology-based thera-
peutics. These include evaluation of nanoparticle biodistribution
following systemic injection, the study of transport across
biological barriers, and the development of imaging modalities
for tracking the fate of nanomedicine over time.
Pharmacokinetic and biodistribution characteristics are impor-
tant parameters to consider when designing and testing novel
nanoparticles. In order to achieve an effective level of nanopar-
ticles in the target tissue or tumor site, targeted nanoparticles
should transition from circulating blood to the tissue of interest
and bind to its molecular target as a first step in nanoparticle
retention or cellular internalization. Unfortunately, many types of
systemically injected nanoparticles are rapidly cleared from the
blood stream by the reticuloendothelial system (RES) and the
mononuclear phagocytic system (MPS) mainly through the liver,
spleen, and bone marrow [1,3] resulting in a low therapeutic
index. Development of nanoparticles that avoid rapid clearance is
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[3,4]. Nanoparticles with an extremely high circulation half-life
should also be avoided as this may contribute to off target tissue
toxicity and reduced signal-to-noise ratio due to non-specific
binding.
Nanoparticle core, linker, and coating materials along with
synthesis and purification techniques influence serum half-life and
biodistribution [5]. Linker molecules like chitosan can sterically
stabilize the corona, and prevent aggregation. Surface modifica-
tion of nanoparticles with synthetic polymers like polyethylene
glycol (PEG), polyvinyl alcohol (PVA), or polysaccharide can
enhance solubility of hydrophobic materials, minimize non-
specific binding, prolong circulation time, and enhance tumor
specific targeting [6,7]. Since chemical and physical properties of
nanoparticles determine their in vivo fate, it is desirable to measure
pharmacokinetic profiles early in the development process so that
this information can be used to influence nanoparticle design and
candidate prototype selection. Traditionally, pharmacokinetic
studies were based on either quantification of the therapeutic
agent (e.g., using HPLC and mass spectroscopy) or by radiolabel-
ing the agent and measuring radioactivity in homogenized tissue
[8,9]. Both approaches are relatively expensive, time consuming,
and outside of the expertise of many nanoparticle synthesis
laboratories. Even though pharmacokinetic data is critical in
making decisions regarding particle size, coating, synthesis
procedures, and purification methods these studies are often
conducted in the late stages of nanoparticle development due to
these roadblocks. Here we describe a new, fast, and economical
method for evaluating PK and biodistribution properties of
nanoparticles using near infrared (NIR) based technology that
allows these critical steps to be performed early in the nanoparticle
development.
Some groups, including ours, incorporate near infrared
fluorophore (NIRF) molecules into nanoparticle synthesis to
facilitate intra-operative visualization of targeted cells or tissues
[10,11]. We capitalized on this reporter molecule to assess serum
half-life and biodistribution of a chitosan-conjugated iron oxide
core nanoparticle. This nanoparticle serves as a platform to deliver
targeted anticancer therapeutics and as an imaging agent for
visualizing tumors in mice [12]. The results suggest potential utility
of these nanoparticles for future medical applications.
This paper describes the development of a new non-radioactive
method for assessing serum half-life, biodistribution and in vivo
stability using the NIRF, Cy5.5. This novel method provides 21-
micron histological resolution for identifying populations of cells
that bind to the nanoparticles. We demonstrate this new technique
by analyzing the tissue distribution and serum half-life of a new
chitosan-conjugated nanoparticle.
Results
Serum Half-Life of Nanoparticles
For assessment of serum half-life, we focused on a reproducible,
quantitative assay that utilized the NIRF dye, Cy5.5, which was
incorporated into the nanoparticle. Blood was collected from mice
at 1, 3, 6, 10, 24, and 48 hours after injection of 200 ml of 1 mg/
ml of NP-chitosan-CTX-Cy5.5 or the non-targeted control, NP-
chitosan-Cy5.5. Blood was centrifuged and the plasma was
collected for analysis. The blood plasma was added to a 96 well
clear bottom plate and scanned using the Odyssey scanner. The
Cy5.5 signal could be readily detected and quantified in small
volume blood samples using a 96 well format NIR fluorescence
scanner as described in the Methods section. NP-chitosan-CTX-
Cy5.5 exhibited a longer circulation time than NP-chitosan-Cy5.5
(Figure 1). Exponential decay analysis of NP-chitosan-CTX-Cy5.5
revealed an elimination half-life of 8 hours compared to 7 hours
for NP-chitosan-Cy5.5.
Biodistribution
Radioactivity-based pre-clinical biodistribution studies typically
fail to show anatomic resolution that would distinguish signal
differences among subpopulations of cells within a tissue. Likewise,
whole organ biophotonic imaging for fluorescence-labeled thera-
peutics also lacks microscopic resolution and further suffers from
the fact that the quantitative data from whole organs is
dramatically affected by size and shape of the organ. After
demonstrating that the Cy5.5 fluorescent signal is retained after
freezing (Figure S1), we developed an assay in which a NIR
fluorescence scanner was used to quantitatively assess Cy5.5 signal
at 21 micrometer resolution.
Mice were injected through the tail vein with 200 ml of 1 mg/ml
NP-chitosan-Cy5.5 or NP-chitosan-CTX-Cy5.5. Whole organs
were removed 6, 24, or 48 hours after injection and scanned using
the IVIS-100 imaging system (Figure 2A). All tissue was frozen in
OCT then sliced in 12-micron sections and mounted on glass
slides. The slides were scanned on the Odyssey NIR scanner and
images were obtained using the 700 nm channel (Figure 2B).
The slice assay revealed, with anatomic resolution, small areas
within certain organs that bind the conjugate that would be missed
by methods that involved homogenization or whole organ
imaging. For example, signal was present in the wall of the aorta
in heart slices (Figure 3C), but not evident on whole organ imaging
(Figure 2). While the amount of signal is small, the data show the
capability of the method to detect small foci of NIRF-positive cells
within an organ that otherwise appears to have minimal signal.
Consistent with whole-organ biophotonic images, significant
localization was seen in slices from the tissues of the RES (liver,
spleen, and bone marrow) as well as the kidneys (Figure 2 and 3).
Histological analysis revealed that binding was not uniform in
these tissues. The binding patterns in liver and spleen suggested
macrophage uptake (Figure 3). High concentration of nanoparti-
cles was revealed in the spleen white pulp. In kidney, the signal
localized to the renal cortex.
Similar to most nanoparticles, tissue binding was higher in
spleen and liver than other tissues. In spleen and liver, NIRF signal
decreased slightly between hour 6 and hour 48 (Figure 4). With the
exception of bone marrow, in which 4–5 fold increase in signal
over background was observed, the signal in all other whole organs
was statistically indistinguishable from background. There was no
significant difference in normal tissue biodistribution between
untargeted and chlorotoxin-targeted nanoparticles indicating that
the targeting peptide influences specific binding to tumors [12,13],
but does not affect non-specific binding to normal tissue (Figure 4).
Nanoparticle Stability
To analyze the stability of nanoparticle suspensions against
agglomeration within the biological system, nanoparticles were
kept in phosphate buffered saline (PBS) of physiologic pH. No
apparent size change was observed after incubation of nanopar-
ticles in media for several months. Nanoparticles were found to be
stable with no sign of aggregation or loss of functionality [12]. The
stability of the Cy5.5-nanoparticle-nanoparticle bond upon storage
in vivo was confirmed by Prussian-blue staining for iron oxide
nanoparticle core and Cy5 fluorescent signal in the liver. Co-
localization of Prussian blue staining and Cy5 fluorescent indicate
that Cy5.5 fluorophores remain attached to iron oxide nanopar-
ticle, confirming the stability of nanoparticles in vivo (Figure 5).
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Guided by the biodistribution data, tissues were carefully
evaluated for evidence of nanoparticle toxicity. Mice received a
single intravenous injection of 200 ml of 1 mg/ml of NP-chitosan-
Cy5.5 or NP-chitosan-CTX-Cy5.5. All mice were evaluated twice
weekly for the duration of the studies for clinical symptoms of
toxicity. None were observed. Seven days after the injection, tissue
was removed and fixed in 10% formalin. A veterinary pathologist
reviewed Hematoxylin and Eosin (H&E)-stained tissue sections
from liver, spleen, kidney, lung, heart, colon, skeletal muscle,
Figure 2. Ex vivo NIRF imaging of each organ. Fluorescence image of whole organs in non-injected (top) or NP-CTX-Chitosan-Cy5.5 injected
(bottom) animals. Images were acquired six hours post injection. (A) Mice were injected 200 ml of 1 mg/ml. Six hours after injection, the animals were
euthanized and the organs were collected. Ex vivo fluorescence images of whole organ was obtained using the Xenogen imaging system. The
spectrum gradient bar corresponds to the fluorescence intensity unit p/sec/cm
2/sr. (B) Fluorescence image of 12-micron sections obtained using the
Odyssey imaging system. The spectrum gradient bar corresponds to relative fluorescent level. (Top row: brain, heart, lung, liver, and kidney. Bottom
row: pancreas, spleen, small intestine, colon, gonad, muscle, and bone marrow) Bone marrow is only shown with the Odyssey scanner.
doi:10.1371/journal.pone.0009536.g002
Figure 1. Serum half life of nanoparticles. (A and B) Standard curve generated by quantifying intensity of known concentrations of NP-chitosan-
Cy5.5 or NP-CTX-chitosan-Cy5.5. (C and D) Measured fluorescence intensity of nanoparticles in serum. Each data point represents the mean
fluorescence intensity integrated above the baseline. This baseline subtraction avoids systematic errors from underlying autofluorescence. Error bars
represent standard errors of the mean. The curve indicates an exponential decay curve fit to the data (n=3 mice per time point).
doi:10.1371/journal.pone.0009536.g001
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9536Figure 3. Comparison of H&E staining and high-resolution NIRF fluorescence imaging. (A) In spleen, NIRF signal was observed in large
cells within the white pulp (bar, 500 mm). (B) In liver, the pattern was less obvious, but clearly heterogeneous (bar, 500 mm). (C) In heart, the muscle
walls of the atria and ventricle showed no signal above background but the walls of the aorta showed significant signal (bar, 50 mm). (D) In kidney,
high NIRF signal was found in the renal cortex (bar, 1 mm). All images were taken of tissues that were harvested 24 hours post nanoparticle injection.
doi:10.1371/journal.pone.0009536.g003
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control or CTX-targeted chitosan-conjugated nanoparticles (data
not shown). Despite relatively high levels of nanoparticles in liver,
spleen, and bone marrow, no significant lesions were observed. In
kidneys, mild multifocal tubular abnormalities were observed in
subsets of both nanoparticle injected and non-injected groups,
leading to the conclusion that these mild differences in histological
appearance were not related to nanoparticle injection. None of the
other tissues had abnormal findings. Overall, the toxicity studies
indicate that the nanoparticles were well tolerated and that renal
function and renal pathology should be closely monitored if the
non-targeted nanoparticles are advanced toward clinical use.
Figure 4. Biodistribution of NP-chitosan-Cy5.5 and NP-CTX-chitosan-Cy5.5 nanoparticles. Relative fluorescence intensity was determined
using the Odyssey scanner. Bars represent tissue from animals that were not injected with nanoparticles (blue), or injected with nanoparticles and
harvested 6 hours (red), 24 hours (green), or 48 hours (purple) after injection. Bars represent the average of 3 animals for each nanoparticle at each
time point. The error bars are standard deviation from the mean. (A) Ex vivo biodistribution of NP-chitosan-Cy5.5 non-targeted nanoparticle. (B) Ex
vivo biodistribution of NP-CTX-chitosan-Cy5.5 targeted nanoparticle.
doi:10.1371/journal.pone.0009536.g004
Figure 5. Co-localization of iron oxide nanoparticle core and Cy5 signal in liver. No iron uptake or Cy5 fluorescent signal was detected in
non-injected control tissue (top row). Co-localization of Prussian blue/hemotoxylin staining and Cy5 signal from the same tissue section suggest that
the nanoparticles remain stable in vivo (bottom row) (bar, 50 mm).
doi:10.1371/journal.pone.0009536.g005
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The goal of our approach is to provide rapid and easy
monitoring of nanoparticle distribution. In the early stages of
nanoparticle development, when decisions are being made about
materials, coatings, synthetic processes and purification, key PK
data can be generated in the same mice that are utilized to assess
nanoparticle targeting to cancer cells or other targets. The stability
of nanoparticles is often studied in biological media such as PBS
and Dulbecco’s modified Eagle’s medium (DMEM) with 10% of
fetal bovine serum (FBS) [14]. However, nanoparticles in solutions
with physiological salt concentration, pH and temperature cannot
fully recapitulate different types of cells or immune system in
biological system. Therefore, we focused on evaluating nanopar-
ticles pharmacokinetic in vivo. In this setting, we found that Cy5.5
signal perfectly matched Prussian Blue staining for the iron oxide
nanoparticles, indicating exceptional in vivo stability. The PK data
can be utilized to inform development and make ‘‘go, no-go’’
decisions. Importantly, serum half-life, biodistribution, and
stability are all evaluated in the same mice, which reduces the
number of research animals utilized (Figure 6) and all data is
generated on a single piece of equipment, which reduces capital
equipment costs.
The serum half-life of NP-chitosan-CTX-Cy5.5 and NP-
chitosan-Cy5.5 is 7–8 hour, which is within the ideal therapeutic
range. We attribute the prolonged serum half-life to the PEG
surface coating with chitosan linker, which was designed to reduce
nanoparticle agglomeration and the rate of nonspecific phagocy-
tosis of the nanoparticles by reticuloendothelial cells. Nanoparticle
serum levels in the first 24 hours, coupled with the biodistribution
data, indicate that both liver and kidney are involved in
nanoparticle elimination. The serum half-life of the tested
nanoparticles was in the range that is generally considered
optimal.
Biodistribution studies revealed expected localization in kidney,
spleen, and liver for both targeted and non-targeted nanoparticles.
High uptake by mononuclear phagocytic system in the liver and
spleen are one of the greatest challenges of using nanoparticles for
tumor targeting. Our new approach allows quantitative measure
of nanoparticles distributed in deep tissues of MPS-rich organs
with anatomical resolution.
The biodistribution findings have different implications for
therapeutics versus imaging. For imaging tumor foci, the primary
concern is the signal in tumor compared to adjacent normal tissue
and it does not matter whether other organs have higher signal
than the tumor unless they are potential sites of metastases or
might obscure visualization of the tumor area by emitting bright
signal. In contrast, targeted therapeutics depends on either having
higher targeting to tumor tissue than all other organs that might be
adversely affected by the therapeutic payload or choosing to
Figure 6. Rapid and easy method to generate key pharmacokinetic data in the early stages of nanoparticle development. Our
approach minimizes the number of mice required to evaluate nanoparticle pharmacokinetic properties. Serum half-life, whole organ biodistribution,
biodistribution at cellular level up to 12 mm resolution, histological and in vivo stability analysis can be performed from the same set of mice that are
used to assess nanoparticle targeting to cancer cells or other targets.
doi:10.1371/journal.pone.0009536.g006
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sequester or excrete nanoparticles nonspecifically.
NIR imaging enables relatively quick and simple measurements
of serum half-life, biodistribution and stability. These data can be
incorporated into early nanoparticle synthesis decisions as well as
more detailed documentation required for nanoparticles that are
submitted to the FDA for human clinical trials. The data obtained
from NIR fluorescence imaging provides sensitive, specific, and
real-time pre-clinical information that complements efficacy
studies focused on tumor visualization.
Materials and Methods
Nanoparticle Synthesis and Characterization
Nanoparticles were synthesized as described previously [12].
Transmission electron microscopy (TEM) has shown the iron oxide
cores with a mean diameter of 7 nm. BCA protein quantification
and fluorescence quantification determined a yield of 16.2 CTX
peptides and 1.5 fluorophores per nanoparticles on average.
Serum Half-Life
All animal studies were conducted in accordance with Fred
Hutchinson Cancer Research Center’s Institute of Animal Care
and Use Committee (IACUC) approved protocols as well as with
federal guidelines. 3–5 month old mice on a C57BL6 background
(Charles River Laboratories, Inc.) were injected through the tail
vein with 200 ml of 1 mg/ml targeted NP-CTX-chitosan-Cy5.5
nanoparticle (n=3) or non-targeted NP-chitosan-Cy5.5 control
nanoparticles (n=3). At six different time points after injection, 1,
3, 6, 12, 24, and 48 hours, blood was collected by retro-orbital eye
bleed or terminal heart puncture. Because of limitations on the
amount of blood that can be drawn from each animal, no animal
was used for more than two time points. Blood samples were
drawn from three independent mice for each time point and
frozen at 280uC until analysis. Samples were thawed at room
temperature for 30 minutes prior to analysis. Whole blood was
spun using a benchtop centrifuge for 5 minutes at 10,000 rpm to
separate the plasma. 50 ml of plasma was then added to a 96 well
clear bottom plate. The plate was scanned on the Odyssey NIR
fluorescence imaging instrument (LI-COR, Lincoln, NE) using the
700 nm-channel (lexc=685 nm with lem=705 nm) to measure
Cy5.5 fluorescence signal. Concentration of nanoparticles was
interpolated from the NP-chitosan-Cy5.5 fluorescence standard
curve. A separate study was done in advance to ensure that
fluorescent signal was not modified by freezing (Figure S1).
Biodistribution of Nanoparticle
Animals were injected via tail vein with 200 ml of 1 mg/ml NP-
CTX-chitosan-Cy5.5 targeted nanoparticle, or NP-chitosan-Cy5.5
non-targeted control nanoparticles. Three additional non-injected
animals were included as controls. 6, 24, or 48 hours after
injection (n=3) the animals were euthanized and tissues were
dissected from twelve different organs: kidney, spleen, liver, colon,
brain, heart, lung, pancreas, muscle, small intestine, gonads, and
bone marrow. Bone marrow was extracted by flushing the bone
marrow cavity with phosphate-buffered saline (PBS) then centri-
fuged to pellet the marrow. Each tissue was imaged using the
IVIS-100 (Xenogen Co., Alameda, CA). Tissues were then
embedded in OCT and kept frozen at -80uC until needed. The
frozen tissues were sliced in 12 mm thick sections and mounted
onto glass slides. The tissue sections were thawed at room
temperature for 30 minutes and the fluorescence intensity was
measured using the Odyssey fluorescence scanner at a resolution
of 21 mm. The images were analyzed with the public-domain
ImageJ software (US National Institutes of Health, Bethesda, MD).
The average fluorescence intensity was determined for each tissue
type using the same threshold settings (low threshold: 400, high
threshold: 20,000). Data are reported as the average channel
fluorescence of the tissue, given as relative units after background
subtraction. For visual illustrations of fluorescence signals, color
maps are generated using Matlab (Mathworks, Natick, MA).
Nanoparticle Stability
Colloidal stability of nanoparticles was evaluated by suspending
the nanoparticles in PBS media of physiologic condition (pH 7.4,
37uC) for several months. For histology and fluorescence imaging
analysis, 12-mm-thick sections were prepared from the same OCT
embedded frozen sample as above. Fluorescence imaging of side-
by-side non-injected controls and injected liver was performed in
the Cy5 channel (lexc=620–650 nm with lem=680–710 nm)
using a TissueFax-System (TissueGnostics, Vienna, Austria). The
same tissue sections were stained with Prussian blue and nuclear
fast red counterstain for visualizing iron nanoparticles. Sections
were then imaged with TissueFax.
Toxicity Studies
Additional Mice were injected with 200 ml of 1 mg/ml NP-
CTX-chitosan-Cy5.5 (n=3) or NP-chitosan-Cy5.5 (n=3) via the
tail vein. Seven days after the injection the following organs were
harvested and fixed in 10% formalin: brain, heart, lung, liver,
spleen, kidney, pancreas, gonad, small intestine, colon, and
muscle. The tissues were paraffin embedded and Hemotoxylin
and Eosin stained according to standard protocols. Each tissue was
analyzed by a veterinary pathologist.
Supporting Information
Figure S1 Freezing effects on NIRF signal. The stability of
infrared signal during the process of freezing was addressed in a
group of mice receiving free Cy5.5 dye and CTX-Cy5.5. Mice
were injected via lateral tail vein with 100 ml of either Cy5.5 or
CTX-Cy5.5. 24 hours post-injection the animals were euthanized
and the kidneys removed. One kidney was homogenized in 1 ml of
PBS, 30 ml was added to a 96 well plate and the NIRF signal was
analyzed using the Odyssey imaging system before and after the
freezing process.
Found at: doi:10.1371/journal.pone.0009536.s001 (0.06 MB
TIF)
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